Thyroid disorders in women with breast cancer;Tyreopatie u žien s karcinómom prsníka

Klinicka Onkologie

Volumn 25, Issue 2, 2012, Pages 124-129

  Hajtmanová, Eva ^a   Murin P ^a   Kinclova I ^a   Hajtman, A ^b   Pec M ^c   Kostkova L ^a   Kocisova M ^a  

^a Onkologicke Centrum   (Slovakia)

^b Pobočka Martin ^*  (Slovakia)

^c JLF UK Martin   (Slovakia)

Author keywords

Autoimmune thyroiditis; Breast cancer; Estrogen receptor; Free thyroxine; HER2 receptor; Hypothyroidism; Progesterone receptor; Thyroid peroxidase; Thyroid stimulating hormone

Indexed keywords

AUTOANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LIOTHYRONINE; PROGESTERONE RECEPTOR; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; FEMALE; HISTOLOGY; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROGNOSIS; THYROID DISEASE; THYROID FUNCTION; THYROID GLAND; AGED; BREAST TUMOR; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; HYPOTHYROIDISM; MIDDLE AGED; PROGNOSIS; THYROIDITIS, AUTOIMMUNE;

EID: 84860540077     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Cristofanilli M, Yamamura Y, Kau SW et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005; 103(6): 1122-1128. (Pubitemid 40328081)
2. Smyth PP. The thyroid, iodine and breast cancer. Breast Cancer Res 2003; 5(5): 235-238. (Pubitemid 37080851)
3. Carvalho ST, Stiepcich MM, Fregnani JH et al. Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. Clinics (Sao Paulo) 2011; 66(4): 607-612.
4. Goldhirsch A, Wood WC, Coates AS et al. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer. highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22(8): 1736-1747.
5. Podoba J. Najčastejšie tyreopatie v ambulanciii praktického lekára. Via Pract 2005; 2(5): 230-235.
6. Hrnčiar J. Racionálna diagnostika funkčných porúch štítnej žl'azy v klinickej praxi. Interní Med 2006; 1: 18-23.
7. Zamrazil V Subklinické tyreopatie. Interní Med 2004; 6: 295-299.
8. Vargová V, Pytliak M, Mechírová V. Hypotyreóza u seniorov. Čes Ger Rev 2010; 8(1-2): 22-26.
9. Riedel C, Dohán O, De la Vieja A et al. Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer. Trends Biochem Sci 2001; 26(8): 490-496. (Pubitemid 32735450)
10. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodine symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006; 13(3): 797-826. (Pubitemid 44763258)
11. Venturi S, Donati FM, Venturi A et al. Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Path 2000; 4(1): 11-17.
12. Smyth PP. Role of iodine in antioxidant defence in thyroid and breast disease. Biofactors 2003; 19(3-4): 121-130. (Pubitemid 38175115)
13. Cann SA, van Netten JP, Glover DW et al. Iodine accumulation in extrathyroidal tissues. J Clin Endokrinol Metab 1999; 84(2): 821-822.
14. Cann SA, van Netten JP, van Netten C. Hypothesis: iodine, selenium and the development of breast cancer. Cancer Causes Control 2000; 11(2): 121-127. (Pubitemid 30088390)
15. Kuijpens JL, Nyklíctek I, Louwman MW et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 2005; 15(11): 1253-1259. (Pubitemid 41821759)
16. Turken O, Narln Y, Demlrbas S et al. Breast cancer in association with thyroid disorders. Breast Cancer Res 2003; 5(5): R110-R113.
17. Smyth PP, Shering SG, Kilbane MT et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J Clin Endocrinol Metab 1998; 83(8): 2711-2716. (Pubitemid 28493765)
18. Cutuli B, Quetin P, Rodier JF et al. Severe hypothyroidism after chemotherapy and locoregional irradiation for breast cancer. Radiother Oncol 2000; 57(1): 103-105.
19. Majkowska-Młynarczyk A, Kinalski M, Zaczek-Kucharska E. The thyroid gland function assessment in women after mastectomy and chemotherapy during breast cancer therapy. Endokrynol Pol 2007; 58(5): 397-402.
20. Zidan J, Rubenstein W Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer. Oncology 1999; 56(1): 43-45. (Pubitemid 29043895)
21. Giustarini E, Pinchera A, Fierabracci P et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol 2006; 154(5): 645-649. (Pubitemid 43810849)
22. Sternberg EM. Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol 2001; 169(3): 429-435. (Pubitemid 32536975)
23. Strieder TG, Prummel MF, Tijssen JG et al. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003; 59(3): 396-401. (Pubitemid 37046995)
24. Galbavý Š. Nové "markery a prognostické faktory" z pohl'adu patológa. Onkológia 2006; 1(3): 151-154.
25. Kajo K, Plank L. Význam analýzy génovej expresie v predpovedi prognózy a liečebnej odpovede pri karcinóme prsnej žl'azy Onkológia 2008; 3(4): 224-229.
26. Chen XS, Ma CD, Wu JY et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone rceptor and Her2 can predict the prognosis of breast cancer. Tumori 2010; 96(1): 103-110.
27. Yang Q, Chen J, Li HJ et al. Clinical features and prognosis analysis of different breast cancer molecular subtypes . Zhonghua Zhong Liu Za Zhi 2011; 33(1): 42-46.
28. Jiskra J. Racionální diagnostika a léčba nemocí štítné žlázy. Med Pro Praxi 2010; 7(4): 167-172.
29. Podoba J. Tyreopatie v ambulancii praktického lekára, alebo ako zvládnut' ich súčasnú "epidé miu"? Via Pract 2009; 6(4): 142-146
30. Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia-a novel paradigm. In Vivo 1996; 10(2): 245-247. (Pubitemid 26169547)
31. Davis FB, Tang HY, Shih A et al. Acting via a cell surface receptor, thyroid hormone is a grow factor for glioma cells. Cancer Res 2006; 66(14): 7270-7275. (Pubitemid 44197708)
32. Gail MH, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst 1994; 86(8): 573-575.
33. Grigerová M, Podoba J. Subklinické poruchy štítnej žl'azy. Lek Obz 2010; 59(11): 444-448.
34. Jiskra J, Límanová Z, Barkmanová J et al Prevalence autoimunitních tyreopatií u žen s karcinomem prsu ve srovnání s kolorektálním karcinomem. Klin Onkol 2003; 16(3): 149-153.
35. Muller I, Pinchera A, Fiore E et al. High prevalence of breast cancer in patients with benign thyroid diseases. J Endocrinol Invest 2010; 15(11): 1253-1259.